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Background: Guidelines suggest that the combination of low-density lipoprotein cholesterol (LDL-C) and non-
high-density lipoprotein cholesterol (non-HDL-C) is the most clinically relevant goal for lipid-lowering
treatments.
Methods:Data fromVOYAGER, an individual patient datameta-analysis including 32,258patients from37 clinical
trials, was used to determine the percentage of patients reaching combined goals of LDL-C and non-HDL-C
following treatment with simvastatin, atorvastatin, or rosuvastatin. Paired comparisons were made between
each dose of rosuvastatin and the same or higher doses of simvastatin and atorvastatin.
Results: Each dose of rosuvastatin brought signiﬁcantlymore patients to the combined goal of LDL-C b100mg/dL
and non-HDL-C b130 mg/dL than the same or double dose of atorvastatin; atorvastatin 80 mg was signiﬁcantly
superior to rosuvastatin 10mg (all p b 0.001). Each dose of rosuvastatin helped signiﬁcantlymore patients reach
the combined goal than any dose of simvastatin (all p b 0.001), except for rosuvastatin 10mg versus simvastatin
80 mg (non-signiﬁcant). Also, each dose of rosuvastatin helped signiﬁcantly more patients to reach the
combined goal of LDL-C b70mg/dL and non-HDL-C b100 mg/dL than the same or double dose of atorvastat-
in (all p b 0.001). Every dose of rosuvastatin was signiﬁcantly superior to all doses of simvastatin (all p≤ 0.020),
except for rosuvastatin 10 mg versus simvastatin 40 mg and 80 mg (non-signiﬁcant).
Conclusions: Physicians' choice of statin and dose is important in helping patients achieve the combined LDL-C
and non-HDL-C goals recommended in established guidelines.
© 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Low-density-lipoprotein cholesterol (LDL-C) has long been the
primary target of cholesterol-lowering therapy and is recommended in
most national and international guidelines [1–3]. However, there is also
evidence that non-high-density lipoprotein cholesterol (non-HDL-C)
maybe an even better predictor of cardiovascular events [4–8]. Therefore,
this measure also has a place in most guidelines [1–3] and was recentlyeliability and freedom from bias
nd ClinicalMedicine, Institute of
burg, SE-413 45, Gothenburg,
.W. Karlson).
nd Ltd. This is an open access article unemphasized as a target in the 2013 position paper by the International
Atherosclerosis Society [8]. In particular, non-HDL-C is claimed to provide
a better risk estimation in certain patient groups, for example, thosewith
hypertriglyceridemia combined with diabetes, the metabolic syndrome,
or chronic kidney disease [2].
Several US guidelines and the European Society of Cardiology (ESC)/
European Atherosclerosis Society (EAS) guidelines suggest a combined
target of LDL-C b100 mg/dL and a non-HDL-C goal 30 mg higher
(b130 mg/dL), especially in patients with elevated triglycerides
[1,2,8,9]. In addition, for very high-risk patients, optional targets
of LDL-C b70mg/dL and non-HDL-C b100mg/dL are included [1,2]. Ac-
cording to these recommendations, very high-risk patients include
those with multiple major risk factors (especially diabetes), severe
and poorly controlled risk factors (especially continued cigarette
smoking), multiple risk factors for metabolic syndrome (especiallyder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Table 1
Baseline characteristics and lipid parameters of patients in the VOYAGER database.
Characteristics n = 32,258
Age (years), mean (SD) 60.0 (11.1)
18–64, % 63.6
65–69, % 15.2
≥70, % 21.2
Men, % 56.7
Race, %
White 79.9
Black 5.1
Hispanic 4.1
Asian 8.3
Other 2.6
Body mass index (kg/m2), mean (SD) 28.8 (5.5)
Diabetes, % 27.5
Atherosclerotic disease, % 48.0
Baseline lipid levels (mg/dL), mean (SD)
LDL-C 170.9 (38.7)
HDL-C 48.7 (12.7)
Non-HDL-C 205.2 (41.8)
TG, median (interquartile range) 162.2 (120.4, 215.0)
ApoB 159.3 (37.2)
ApoA-1 148.8 (28.7)
Apo = apolipoprotein; HDL-C = high-density lipoprotein cholesterol; LDL-C = low-
density lipoprotein cholesterol; SD = standard deviation; TG = triglycerides.
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HDL-C [b40 mg/dL]) and acute coronary syndromes.
More recently, there have been reports of suboptimal achievement
of the combined LDL-C and non-HDL-C goal in hypertriglyceridemic
and high-risk patients [10,11]. This may be partly due to lack of aware-
ness of the non-HDL-C goal [10,12], but there may also be variability in
the effectiveness of different lipid-lowering treatments on non-HDL-C.
The aim of the present analysis was to evaluate whether there are
differences between statins in their ability to help patients to reach
combined LDL-C and non-HDL-C goals using the VOYAGER (an indi-
Vidual patient data meta-analysis Of statin therapY in At risk Groups:
Effects of rosuvastatin, atorvastatin and simvastatin) meta-analysis
database.
2. Methods
2.1. Study design
VOYAGER is an individual patient data meta-analysis including
32,258 patients from 37 clinical trials. The patients included and
methods have been reported previously [13]. Only studies of ﬁxed-
dose comparisons of rosuvastatin with either simvastatin or atorvastat-
in that also recorded lipid parameters at baseline and on therapy for in-
dividual patients were included in the database.
All lipid parameters were quantiﬁed on samples collected in the
fasting state. Cholesterol and triglyceride quantitation was determined
by enzymatic assay. LDL-C was calculated using the Friedewald
equation for patients with triglycerides ≤400 mg/dL and measured by
quantiﬁcation for those with triglycerides N400 mg/dL. HDL-C was
quantiﬁed after the precipitation of apolipoprotein (Apo) B-containing
lipoproteins. Levels of non-HDL-C were calculated by the subtractionTable 2
Least squares mean percentage change from baseline in LDL-C and non-HDL-C.
Least squares mean (SE) % change from baseline
ATV
10 mg
ATV
20 mg
ATV
40 mg
ATV
80 mg
RSV
10 mg
No. of patients 7677 3607 1100 1853 11,437
LDL-C −35.9 −42.1 −46.4 −50.5 −44.5
Non-HDL-C −33.4 −38.9 −42.7 −47.0 −40.8
ATV = atorvastatin; LDL-C = low-density lipoprotein cholesterol; non-HDL-C = non-high-deof HDL-C from total cholesterol. ApoB levels at baseline were quantiﬁed
by immunonephelometry.
2.2. Objective
The objective of this analysis was to determine the percentage of
patients from the VOYAGER database reaching combined goals of
LDL-C and non-HDL-C b100 and b130 mg/dL and b70 and b100 mg/dL,
respectively, during treatment with simvastatin 10, 20, 40, and 80 mg,
atorvastatin 10, 20, 40, and 80 mg, or rosuvastatin 10, 20, and 40 mg.
2.3. Statistical analysis
Least squares mean percentage change in LDL-C and non-HDL-C for
each statin and dose was obtained from a mixed effects model.
For dual goal achievement, paired comparisonsweremade between
each dose of rosuvastatin and the same or higher milligram doses of
simvastatin or atorvastatin, with logistic regression models utilizing
only studies directly comparing the pair of treatments by randomized
design. All analyses were performed on the total VOYAGER population.
Because some studies included forced titration, there were a total of
35,093 patient exposures to individual statin doses among the 32,258
patients included in the database. Each model had ﬁxed effects for
trial and treatment (two levels) and estimated the odds ratio for achiev-
ing the combined goals. Odds ratios are displayed in forest plots for
rosuvastatin versus atorvastatin, and rosuvastatin versus simvastatin,
with 95% conﬁdence intervals.
3. Results
3.1. Patients
Baseline characteristics and lipid parameters of thepatients included
in the analysis are shown in Table 1.
3.2. LDL-C and non-HDL-C reductions
Least squares mean (LSM) reductions in LDL-C and non-HDL-C for
each statin dose in this patient population are shown in Table 2.
For some statins and doses, LSM reductions in LDL-C and non-HDL-C
were greater in females and in patients older than 65 years. Some of
these effects reached statistical signiﬁcance, but they were small
(b2.4%), and not consistent across statins and doses. Atherogenic dys-
lipidemia status had no effect on the LSM reductions in LDL-C and
non-HDL-C.
3.3. Combined goal of LDL-C b100 mg/dL and non-HDL-C b130 mg/dL
The percentages of patients reaching the combined goal of
LDL-C b100 mg/dL and non-HDL-C b130 mg/dL are shown in Fig. 1.
Fig. 2 shows paired comparisons of each dose of rosuvastatin with an
equal or higher dose of atorvastatin or simvastatin, including only
those studies that directly randomized patients to the treatments being
compared. Each dose of rosuvastatin brought signiﬁcantlymore patients
to the combined goal than the same or double dose of atorvastatin (allRSV
20 mg
RSV
40 mg
SIM
10 mg
SIM
20 mg
SIM
40 mg
SIM
80 mg
2886 2463 165 2885 542 478
−50.1 −54.9 −27.8 −33.3 −39.4 −45.3
−45.7 −50.2 −25.4 −30.6 −35.8 −41.0
nsity lipoprotein cholesterol; RSV = rosuvastatin; SIM = simvastatin.
Fig. 2. Odds ratio for low-density lipoprotein cholesterol b100 mg/dL and non-high-densit
rosuvastatin compared with equal and higher doses of (A) atorvastatin and (B) simvastatin. AT
Fig. 1. Percentages of patients achieving both low-density lipoprotein cholesterol b100
mg/dL and non-high-density lipoprotein cholesterol b130 mg/dL goals.
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10 mg (p b 0.001) (Fig. 2a).
Likewise, each dose of rosuvastatin helped signiﬁcantly more
patients to reach the combined goal than any dose of simvastatin (all
p b 0.001), with the exception of rosuvastatin 10mg versus simvastatin
80 mg (p = non-signiﬁcant [NS]) (Fig. 2b).
Interaction tests showed that the results applied equally whether
patients were considered high-risk or not. The percentages of pa-
tients reaching the individual goals of LDL-C b100 mg/dL or non-
HDL-C b130 mg/dL with each dose of rosuvastatin, simvastatin, or
atorvastatin are shown in Table 3.
3.4. Combined goal of LDL-C b70 mg/dL and non-HDL-C b100 mg/dL
The percentages of patients reaching the lower combined goal of
LDL-C b70 mg/dL and non-HDL-C b100 mg/dL are shown in Fig. 3.y lipoprotein cholesterol b130 mg/dL goal achievement, with 95% conﬁdence interval:
V = atorvastatin; RSV = rosuvastatin; SIM = simvastatin.
Table 3
Patients (%) achieving combined low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol goals.
Goal ATV
10 mg
ATV
20 mg
ATV
40 mg
ATV
80 mg
RSV
10 mg
RSV
20 mg
RSV
40 mg
SIM
10 mg
SIM
20 mg
SIM
40 mg
SIM
80 mg
No. of patients 7677 3607 1100 1853 11,437 2886 2463 165 2885 542 478
LDL-C b100 mg/dL and non-HDL-C b130 mg/dL
LDL-C
b100 mg/dL
43.1 61.6 67.8 77.3 65.7 80.1 81.8 7.9 35.1 47.2 42.5
Non-HDL-C
b130 mg/dL
48.6 65.0 70.4 78.8 67.8 80.9 82.5 9.7 39.3 49.3 44.8
Both 38.2 56.8 62.7 74.2 61.0 76.6 78.8 5.5 30.0 41.0 37.0
LDL-C b70 mg/dL and non-HDL-C b100 mg/dL
LDL-C
b70 mg/dL
6.1 14.5 17.7 30.8 21.8 38.0 38.9 0.0 3.7 7.6 2.9
Non-HDL-C
b100 mg/dL
11.1 22.5 26.1 40.5 28.9 43.8 47.5 0.6 7.3 11.8 7.3
Both 4.9 12.3 15.5 27.6 18.6 33.6 35.1 0.0 2.8 6.3 1.7
ATV = atorvastatin; LDL-C = low-density lipoprotein cholesterol; non-HDL-C = non-high-density lipoprotein cholesterol; RSV = rosuvastatin; SIM = simvastatin.
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equal or higher dose of atorvastatin or simvastatin, including only
those studies that directly randomized patients to the treatments
being compared. With each dose of rosuvastatin, signiﬁcantly more
patients achieved this combined goal than the same or double dose
of atorvastatin (all p b 0.001). Atorvastatin 40mg and 80mgbrought sig-
niﬁcantly more patients to goal than rosuvastatin 10mg (p= 0.038 and
p b 0.001, respectively), with no signiﬁcant difference between
rosuvastatin 20 mg and atorvastatin 80 mg (p = NS).
In addition, signiﬁcantly more patients achieved the combined goal
for every dose comparison between rosuvastatin and equal or higher
doses of simvastatin (all p ≤ 0.020), with the exception of rosuvastatin
10 mg versus simvastatin 40 mg and 80 mg (p = NS).
Once again, interaction tests showed that the results applied equally
whether patients were considered high-risk or not. The percentages of
patients reaching the individual goals of LDL-C b70 mg/dL or non-
HDL-C b100 mg/dL with each dose of rosuvastatin, simvastatin, or
atorvastatin are shown in Table 3.
4. Discussion
The results of this analysis suggest that treating patients with amore
potent statin and at an adequate dose may be beneﬁcial in helping
patients to achieve the combined LDL-C and non-HDL-C goals recom-
mended in several guidelines [1–3], and also in reaching each of these
goals individually.
In a previous analysis from VOYAGER, increasing statin potency and
dose were shown to be beneﬁcial in terms of achievement of the
European goal for high-risk patients of LDL-C b70 mg/dL or ≥50% re-
duction in LDL-C, with statistically signiﬁcant differences betweenFig. 3. Percentages of patients achieving both low-density lipoprotein cholesterol b70mg/dL
and non-high-density lipoprotein cholesterol b100 mg/dL goals.rosuvastatin and equal or doublemilligramdoses of atorvastatin or sim-
vastatin [14].
As demonstrated in Figs. 1 and 3, it is not always easy to get patients
to the suggested combined goals, especially the lower combined goal of
LDL-C b70 mg/dL and non-HDL-C b100 mg/dL recommended for high-
risk patients; even with the help of the highest doses of statins, a sub-
stantial number of patients do not reach the combined goals. Future
studies and experience will conﬁrm if add-on therapy with newer
drugs with complementary mechanisms of action will help more pa-
tients to reach these goals, and in doing so whether they will reduce
the overall risk of cardiovascular events.
Previous studies have indicated that the non-HDL-C goal may be
more difﬁcult to attain than the LDL-C goal [11,15]. In contrast, the
present study showed that slightly more patients achieved the non-
HDL-C goals (b130 and b100 mg/dL) than the LDL-C goals (b100 and
b70 mg/dL).
LSM reductions in LDL-C and non-HDLC were slightly greater in fe-
males and in patients older than 65 years. These effects reached statisti-
cal signiﬁcance because of large sample sizes, but they were small
(b2.4%), not consistent across statins and doses, and therefore we feel
of very limited clinical relevance.
Although the 2013 American College of Cardiology and American
Heart Association guidelines differ from other recent guidelines in that
they do not recommend treating patients to a speciﬁc LDL-C goal,
current guidelines are uniform in that they all focus on using statin
treatment to reduce LDL-C and thereby reduce cardiovascular risk [2,3,
8,16]. The importance of non-HDL-C as a superior risk indicator has
also been recently emphasized [8].
A limitation of the present study is that patients were not stratiﬁed
according to overall cardiovascular risk or baseline triglyceride level.
Another limitation of this meta-analysis is that the VOYAGER database
does not hold safety or outcome data so comparisons in these respects
between statins are not possible.
In conclusion, physicians' choice of statin and dose is important in
helping patients achieve the recommended combined LDL-C and non-
HDL-C goals.
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